» Articles » PMID: 20951794

CD14 and TRIF Govern Distinct Responsiveness and Responses in Mouse Microglial TLR4 Challenges by Structural Variants of LPS

Overview
Publisher Elsevier
Date 2010 Oct 19
PMID 20951794
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Toll-like receptor (TLR) 4 responds to a range of agonists in infection and injury, but is best known for the recognition of bacterial lipopolysaccharides (LPS). Assembly in heterologous receptor complexes as well as signaling through both MyD88 and TRIF adaptor proteins, as unmatched by other TLRs, could underlie its versatile response options, probably also in a cell type-dependent manner. We show that microglia, the CNS macrophages, react to diverse LPS variants, including smooth (S) and rough (R) LPS chemotypes, with cytokine/chemokine induction, MHC I expression and suppression of myelin phagocytosis. The TLR4 co-receptor CD14 was shown in peritoneal macrophages to be essential for S-LPS effects and the link of both S- and R-LPS to TRIF signaling. In contrast, cd14(-/-) microglia readily respond to S- and R-LPS, suggesting an a priori high(er) sensitivity to both chemotypes, while CD14 confers increased S- and R-LPS potencies and compensates for their differences. Importantly, CD14 controls the magnitude and shapes the profile of cyto/chemokine production, this influence being itself regulated by critical LPS concentrations. Comparing reactive phenotypes of microglia with deficiencies in CD14, MyD88 and TRIF (cd14(-/-), myd88(-/-), and trif(lps2)), we found that distinct signaling routes organize for individual functions in either concerted or non-redundant fashion and that CD14 has contributions beyond the link to TRIF. Modulation of response profiles by key cytokines finally reveals that the microglial TLR4 can differentiate between the class of LPS structures and a self-derived agonist, fibronectin. It thus proves as a sophisticated decision maker in infectious and non-infectious CNS challenges.

Citing Articles

Gut microbiota metabolites: potential therapeutic targets for Alzheimer's disease?.

Zhang S, Lu J, Jin Z, Xu H, Zhang D, Chen J Front Pharmacol. 2024; 15:1459655.

PMID: 39355779 PMC: 11442227. DOI: 10.3389/fphar.2024.1459655.


β-chitosan attenuates hepatic macrophage-driven inflammation and reverses aging-related cognitive impairment.

Zou C, Cai R, Li Y, Xue Y, Zhang G, Alitongbieke G iScience. 2024; 27(9):110766.

PMID: 39280626 PMC: 11401205. DOI: 10.1016/j.isci.2024.110766.


Activation of the hypoxia-inducible factor pathway protects against acute ischemic stroke by reprogramming central carbon metabolism.

Madai S, Kilic P, Schmidt R, Bas-Orth C, Korff T, Buttner M Theranostics. 2024; 14(7):2856-2880.

PMID: 38773968 PMC: 11103502. DOI: 10.7150/thno.88223.


Intralesional TLR4 agonist treatment strengthens the organ defense against colonizing cancer cells in the brain.

Blazquez R, Chuang H, Wenske B, Trigueros L, Wlochowitz D, Liguori R Oncogene. 2022; 41(46):5008-5019.

PMID: 36224342 PMC: 9652147. DOI: 10.1038/s41388-022-02496-3.


MicroRNA miR-27b-3p regulate microglial inflammation response and cell apoptosis by inhibiting A20 (TNF-α-induced protein 3).

Li L, Qi C, Liu Y, Shen Y, Zhao X, Qin H Bioengineered. 2021; 12(2):9902-9913.

PMID: 34895052 PMC: 8810141. DOI: 10.1080/21655979.2021.1969195.